期刊文献+

槲皮素对TRAMP-C2前列腺癌细胞的抑制作用 被引量:11

Inhibitory effect of quercetin on angiogenesis in TRAMP-C2 prostate cancer cells in vivo
原文传递
导出
摘要 目的探讨槲皮素对TRAMP-C2前列腺癌小鼠模型的抑制作用及其机制。方法建立前列腺癌细胞株TRAMP-C2小鼠模型并随机分成4组。A组(对照组);B组(槲皮素25 mg/ kg体重治疗组);C组(槲皮素50 mg/kg体重治疗组);D组(槲皮素100 mg/kg体重治疗组)。观察槲皮素对各组小鼠的抑瘤作用并检测各组肿瘤标本的微血管密度计数。结果接种5周后A、B、C、D各组小鼠的肿瘤重量分别为(1.85±0.23)、(1.61±0.10)、(1.10±0.17)、(0.79±0.11)g,治疗组明显低于对照组(P<0.01),B、C、D组的抑瘤率分别为13%、41%、57%。各组肿瘤的微血管密度计数分别为39.29±6.39,31 61±4.82,23.42±3.91,14.00±4.01,治疗组明显减少(P<0.05)。结论槲皮素可抑制前列腺癌细胞株TRAMP-C2小鼠移植瘤的生长;其机制可能与抑制肿瘤组织血管生成有关。 Objective To study the effect of quereetin on the growth of tumors established by TRAMP-C2 cells in mice and to explore the mechanisms of the effect. Methods TRAMP-C2 prostate cancer model was set up and the mice were randomly divided into four groups. Group A was used as control;25 mg/kg quereetin was given to each mouse in group B,while 50 mg/kg quereetin in group C and 100 mg/kg quereetin in group D. The inhibitory effect on tumors in each group was studied. Mierovessel density (MVD) was calculated by immunoehemieal methods. Results Quereetin inhibited the growth of mouse prostate cancer in vivo. The weight of tumors in the study groups was significant less than in the control group (P〈 0.01). MVD in the study groups was decreased significantly (P〈 0.01). The inhibitory effect was dose-dependent, and the inhibitory rate in groups B, C and D was 13 %, 41% and 57 % respectively. Conclusion The mechanism by which quereetin inhibits the growth of TRAMP-C2 prostate cancer cells in vivo might be related to the inhibition of tumor angiogenesis.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2006年第10期1240-1241,共2页 Chinese Journal of Experimental Surgery
基金 北京市科委新星计划资助项目(H020821180190)
关键词 槲皮素 前列腺癌 血管生成 Quercetin Prostate carcinoma Angiogenesis
  • 相关文献

参考文献4

二级参考文献14

  • 1Zhong H,Cancer Res,2000年,60卷,1541页
  • 2Abe J,Cancer Res,1994年,54卷,3407页
  • 3Vogt TM, Ziegler RG, Graubard BI, et al. Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer, 2003, 103:664-670.
  • 4Nomura AM, Lee J, Stemmermann GN, et al. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2000, 9:883-887.
  • 5Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health, 1991, 46:37-42.
  • 6El-Bayoumy K, Upadhyaya P, Chae YH, et al. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem, 1995, 22(Suppl):92-100.
  • 7Nayini JR, Sugie S, el-Bayoumy K, et al. Effect of dietary benzylselenocyanate on azoxymethane-induced colon carcinogenesis in male F344 rats. Nutr Cancer, 1991, 15:129-139.
  • 8Foster BA, Gingrich JR, Kwon ED, et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res, 1997, 57: 3325-3330.
  • 9周金煦, 陈瑞婷. 动物移植性肿瘤实验法. 见: 徐叔云, 卞如濂, 陈修, 主编. 药理实验方法学. 第2版. 北京: 人民卫生出版社, 1991. 1423-1436.Zhou JX, Chen RT. Experimental methods for transplanted tumors in animals. In: Xu SY, Bian RL, Chen X, eds. Experimental methology in pharmacology. 2nd ed. Beijing: People′s Medical Publishing House, 1991. 1423-1436.
  • 10Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res, 1998, 58: 3344-3352.

共引文献16

同被引文献102

引证文献11

二级引证文献114

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部